Lantern Pharma spins out AI platform as Open-Medicine AI, signs commercial licenses

Lantern Pharma Inc.

Lantern Pharma (LTRN) creates Open-Medicine AI as a separate company to commercialize its multi-agent AI co-scientist platform.
Commercial licensing agreements executed between Lantern and OMAI for withZeta.ai-related models, data, and assets.
Board approved; structure consistent with May 2026 registered direct financing led by Empery Asset Management.
OMAI to expand beyond oncology into other disease areas; global AI drug discovery market projected >$10B by 2030.
AI Center of Excellence in Bengaluru, India established in Q1 2026 to support platform scaling.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.